Pharma Journalist -

Formation Bio and Lynk Pharmaceuticals have announced that Formation Bio has acquired worldwide rights—excluding Greater China—to LNK01006, a next-generation, central nervous system…
Read More...

China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast), marking the first new treatment for adults with progressive pulmonary fibrosis (PPF) in…
Read More...

Nanexa AB has entered into a new license and option agreement with Moderna Inc., marking a significant expansion of its long-acting injectable drug-delivery partnerships. The deal…
Read More...

China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi therapies—Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired…
Read More...

Pfizer has released compelling new data from its Phase 3 HER2CLIMB-05 clinical trial, showing that the company’s tyrosine kinase inhibitor, TUKYSA® (tucatinib), significantly improved…
Read More...

Zydus Lifesciences has announced a major strategic partnership with Germany-based Formycon AG to develop and commercialize FYB206, a biosimilar version of the blockbuster immunotherapy…
Read More...

Ajax Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095, the company’s next-generation JAK inhibitor being…
Read More...

Eli Lilly and Company has announced plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, aimed at producing next-generation synthetic medicine active…
Read More...

Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its epinephrine injection USP, 1 mg/mL, in both single-dose (1 mL) and multi-dose (30 mL)…
Read More...

Pfizer has entered into a global collaboration and licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, to advance the development of YP05002, an…
Read More...